The global hydrocephalus market was valued at $6907.5 million in 2020 and is projected to reach $10178.6 million by 2030, registering a CAGR of 4.0% from 2021 to 2030.
Hydrocephalus is a chronic, neurological disorder caused by an abnormal accumulation of cerebrospinal fluid (CSF) within cavities of the brain called ventricles. This increase in volume results on elevated pressure within the cranium, which can cause irreversible damage to the brain tissue. The human body produces 500 ml of CSF on daily basis, with continuous replacement of the fluid as it is absorbed. In normal conditions, there is a subtle balance between the amount of fluid produced and the rate at which it is absorbed within the body. Hydrocephalus occurs when there is a disruption in this balance. Hydrocephalus can be treated in a variety of ways based on the aetiology of the disorder. But it is most commonly treated indirectly by implanting a medical device known as a “shunt” to divert the excess CSF away from the brain. A shunt, is a flexible tube, which is placed in the ventricular system of the brain that diverts the flow of CSF to another region of the body, most often the abdominal cavity, or heart, where it can be absorbed. Moreover, other treatment options for hydrocephalus include ventriculostomy and medications. One of the prominent factors responsible for the growth hydrocephalus market includes the increase in the number of hydrocephalic patients, which subsequently leads to the increase in the number of shunting procedures across the world. For instance, according to the hydrocephalus association, in 2021, over 36,000 shunt surgeries are performed each year (one every 15 minutes) and more than half of them represent emergencies.
Moreover, high demand for neurosurgery devices & accessories for hydrocephalus management and a rise in cases of neurological disorders, owing to congenital abnormalities and lifestyle diseases as well as a rise in incidences of brain and nerve injuries, boosts the demand for hydrocephalic shunts.
Furthermore, the key developmental strategies such as product approval, partnership, and launch of various novel hydrocephalic valves by key players are further projected to propel the growth of the market. For instance, in 2021, Anuncia Inc., an emerging leader in Cerebral Spinal Fluid (CSF) management, received U.S. Food and Drug Administration (FDA) breakthrough device designation for its ReFlow System Mini intended for the treatment of CSF disorders requiring shunting such as hydrocephalus.
Furthermore, in 2020, Aesculap, Inc., in partnership with the Christoph Miethke GmbH & Co. KG (MIETHKE), announced the launch of the M.blue valve, the latest generation of Hydrocephalus valve technology. Its unique gravitational technology is integrated with a fixed differential pressure unit in one valve, allowing for a simple, position-dependent solution. These strategies are certainly enhancing the company’s footprints in the Hydrocephalus market, thereby contributing to the overall growth of the market.
However, serious damages caused by infections and malfunctions of existing shunts greatly limit the market growth. Some deleterious complications include irreversible brain injuries, meningitis, endocarditis, traumatic perforation, tricuspid regurgitation, heart failure, pulmonary hypertension, and others. For instance, according to the Hydrocephalus Association, approximately 50% of shunts in the pediatric population fail within two years of placement, requiring repeated neurological operations. On the contrary, advancements in shunt technology for reducing shunt complications are projected to create lucrative opportunities for market growth.
The hydrocephalus market is segmented on the basis of cause, type, diagnosis, treatment, age and region. On the basis of cause, the market is categorized into congenital hydrocephalus and acquired hydrocephalus. By type, the market is segmented into communicating hydrocephalus and non-communicating hydrocephalus. The communicating hydrocephalus is categorized into normal pressure hydrocephalus, ex-vacuo hydrocephalus. The diagnosis segment is fragmented into CT scan, MRI, and ultrasound. Furthermore, on the basis of treatment, the market is categorized into surgery shunt insertion and ventriculostomy.
The age is categorized into Neonate & Pediatrics and Adults. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global hydrocephalus shunt market are Aesculap Inc., Integra Lifesciences, Karl Storz Se And Co. Kg, Proteses Inc., Medtronic Plc. and Natus Medical Inc. Further, the service provider of hydrocephalus is Boston Children’s Hospital, Anadolu Medical Center, Helios Hospital, Texas Children's Hospital, and Children's National Hospital.
Hydrocephalus is a chronic, neurological disorder caused by an abnormal accumulation of cerebrospinal fluid (CSF) within cavities of the brain called ventricles. This increase in volume results on elevated pressure within the cranium, which can cause irreversible damage to the brain tissue. The human body produces 500 ml of CSF on daily basis, with continuous replacement of the fluid as it is absorbed. In normal conditions, there is a subtle balance between the amount of fluid produced and the rate at which it is absorbed within the body. Hydrocephalus occurs when there is a disruption in this balance. Hydrocephalus can be treated in a variety of ways based on the aetiology of the disorder. But it is most commonly treated indirectly by implanting a medical device known as a “shunt” to divert the excess CSF away from the brain. A shunt, is a flexible tube, which is placed in the ventricular system of the brain that diverts the flow of CSF to another region of the body, most often the abdominal cavity, or heart, where it can be absorbed. Moreover, other treatment options for hydrocephalus include ventriculostomy and medications. One of the prominent factors responsible for the growth hydrocephalus market includes the increase in the number of hydrocephalic patients, which subsequently leads to the increase in the number of shunting procedures across the world. For instance, according to the hydrocephalus association, in 2021, over 36,000 shunt surgeries are performed each year (one every 15 minutes) and more than half of them represent emergencies.
Moreover, high demand for neurosurgery devices & accessories for hydrocephalus management and a rise in cases of neurological disorders, owing to congenital abnormalities and lifestyle diseases as well as a rise in incidences of brain and nerve injuries, boosts the demand for hydrocephalic shunts.
Furthermore, the key developmental strategies such as product approval, partnership, and launch of various novel hydrocephalic valves by key players are further projected to propel the growth of the market. For instance, in 2021, Anuncia Inc., an emerging leader in Cerebral Spinal Fluid (CSF) management, received U.S. Food and Drug Administration (FDA) breakthrough device designation for its ReFlow System Mini intended for the treatment of CSF disorders requiring shunting such as hydrocephalus.
Furthermore, in 2020, Aesculap, Inc., in partnership with the Christoph Miethke GmbH & Co. KG (MIETHKE), announced the launch of the M.blue valve, the latest generation of Hydrocephalus valve technology. Its unique gravitational technology is integrated with a fixed differential pressure unit in one valve, allowing for a simple, position-dependent solution. These strategies are certainly enhancing the company’s footprints in the Hydrocephalus market, thereby contributing to the overall growth of the market.
However, serious damages caused by infections and malfunctions of existing shunts greatly limit the market growth. Some deleterious complications include irreversible brain injuries, meningitis, endocarditis, traumatic perforation, tricuspid regurgitation, heart failure, pulmonary hypertension, and others. For instance, according to the Hydrocephalus Association, approximately 50% of shunts in the pediatric population fail within two years of placement, requiring repeated neurological operations. On the contrary, advancements in shunt technology for reducing shunt complications are projected to create lucrative opportunities for market growth.
The hydrocephalus market is segmented on the basis of cause, type, diagnosis, treatment, age and region. On the basis of cause, the market is categorized into congenital hydrocephalus and acquired hydrocephalus. By type, the market is segmented into communicating hydrocephalus and non-communicating hydrocephalus. The communicating hydrocephalus is categorized into normal pressure hydrocephalus, ex-vacuo hydrocephalus. The diagnosis segment is fragmented into CT scan, MRI, and ultrasound. Furthermore, on the basis of treatment, the market is categorized into surgery shunt insertion and ventriculostomy.
The age is categorized into Neonate & Pediatrics and Adults. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global hydrocephalus shunt market are Aesculap Inc., Integra Lifesciences, Karl Storz Se And Co. Kg, Proteses Inc., Medtronic Plc. and Natus Medical Inc. Further, the service provider of hydrocephalus is Boston Children’s Hospital, Anadolu Medical Center, Helios Hospital, Texas Children's Hospital, and Children's National Hospital.
Key benefits for stakeholders
- The study provides an in-depth analysis of the global hydrocephalus market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict market growth is provided in the report.
- A comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps understand the different types of hydrocephalus across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
Key market segments
By Cause
- Congenital hydrocephalus
- Acquired hydrocephalus
By type
- Communicating hydrocephalus
- Normal Pressure hydrocephalus
- Ex-vacuo hydrocephalus
- Non- Communicating hydrocephalus
By Diagnosis
- CT Scan
- MRI
- Ultrasound
By Treatment
- Surgery shunt insertion
- Ventriculostomy
By AGE
- Neonate & Pediatrics
- Adults
By Service Provider
- Boston Children’s Hospital
- Anadolu Medical Center
- Helios Hospital
- Texas Children's Hospital
- Children's National Hospital
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
List of key players profile and Service provider in the report
- Aesculap Inc.
- Integra Lifesciences
- Karl Storz Se And Co. Kg
- Medtronic Plc
- Natus Medical Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: HYDROCEPHALUS MARKET, BY CAUSE
CHAPTER 5: HYDROCEPHALUS MARKET, BY TYPE
CHAPTER 6: HYDROCEPHALUS MARKET, BY DIAGNOSIS
CHAPTER 7: HYDROCEPHALUS MARKET, BY TREATMENT
CHAPTER 8: HYDROCEPHALUS MARKET, BY AGE
CHAPTER 9: HYDROCEPHALUS MARKET, BY REGION
CHAPTER 10: COMPANY PROFILES
CHAPTER 11: COMPANY PROFILES: SERVICE BASED
List of Tables
List of Figures
Companies Mentioned
- Aesculap Inc.
- Integra Lifesciences
- Karl Storz Se And Co. Kg
- Proteses Inc.
- Medtronic Plc
- Natus Medical Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 280 |
| Published | December 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 6907.5 million |
| Forecasted Market Value ( USD | $ 10178.6 million |
| Compound Annual Growth Rate | 4.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 6 |
